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ABSTRACT
This study was performed to assess the interactions that occur
between delta-and mu opioid receptors by studying effects of
the systemically active nonpeptide delta agonist BW373U86
and the mu agonist fentanyl in mice. Concentrations of the
compounds were varied, and analgesic responses were deter-
mined by 55°C hot-plate assays. BW373U86 produced hot-
plate antinociceptive activity along with convulsive side effects.
These effects could be antagonized by the selective delta an-
tagonist naltrindole. Fentanyl produced hot-plate antinocicep-
tive activity with Straub tail and hyperactivity as side effects.
When BW373U86 and fentanyl were coadministered,
BW373U86 convulsive activity was attenuated by fentanyl in a
dose-dependent manner and the fentanyl-induced Straub tail
effect was antagonized by BW373U86, also in a dose-depen-
dent manner. Hot-plate analgesic activity was additive between
the two compounds. The delta antagonist naltrindole partially
antagonized the ability of BW373U86 to block the fentanyl-
induced Straub tail effect. The mu antagonist b- funaltrexamine
antagonized the fentanyl-induced blockade of the convulsive
effects of BW373U86. These data suggest that complex inhib-
itory interactions take place between mu and delta receptors in
mice. Future studies are clearly needed to study the neuro-
modulatory effects of mu and delta receptors. The widespread
use of mu agonists in the clinic indicates that a large number of
patients exist who could greatly benefit from the conjunctive
use of delta pharmaceuticals.
Accumulating evidence suggests that interactions occur
between mu- and delta opioid receptors (Lee and Smith,
1980; Rothman and Westfall, 1982; Vaught et al., 1982).
There also are considerable data indicating that the antino-
ciceptive effects of certain mu agonists can be increased or
decreased by delta agonists. The first investigators to report
such action (Vaught and Takemori, 1979) showed that an
intracerebroventricular injection of [Leu5]enkephalin poten-
tiates the antinociceptive action of morphine. Later, studies
showed that the antinociceptive action of morphine can be
antagonized by [Met5]enkephalin (Lee et al., 1980; Vaught et
al., 1982). The agonistic and antagonistic effects of [Leu5]
and [Met5]enkephalins apparently occur through the actions
of delta receptors, because the effects can be blocked by
selective delta antagonists (Cotton et al., 1984; Heyman et
al., 1989a, 1989b; Jiang et al., 1990b; Portoghese et al.,
1988b). All of these results indicate that antinociception can
be modulated by an interaction between delta and mu recep-
tors. However, only a few studies have investigated the in-
teractive effects of delta receptor activation on other mu
opioid effects; these studies include modulation of endotoxic
shock in rats (D’Amato and Holaday, 1984; Holaday et al.,
1986; Holaday and D’Amato, 1983) and modulation of mu-




novel nonpeptide delta agonist that can cross the blood-brain
barrier. In vitro evidence shows that BW373U86 has a higher
affinity for delta opioid receptors (Ki 5 1.8 nM) than for mu
opioid receptors (Ki 5 15 nM) in rat brain (Chang et al.,
1993). BW373U86 is ;700 times more potent at delta recep-
tors of mouse vas deferens than at mu receptors of guinea pig
ileum (Chang et al., 1993). In vivo pharmacological studies
indicate that BW373U86 primarily acts at delta receptors to
produce a variety of effects in different species (Comer et al.,
1993a, 1993b; Dykstra et al., 1993; Lee et al., 1993; Negus et
al., 1993). The mild analgesic effects of BW373U86 are pri-
marily mediated by delta opioid receptors at the spinal level
(Wild et al., 1993). In rats, increased locomotor activity and
inhibition of acoustic startle reflex are seen after s.c. or
intraperitoneal administration of BW373U86, but no antino-
ciceptive activity occurs in the hot-plate, tail-withdrawal,
tail-flick or tail-pinch assays (Chang et al., 1993). In vivo
characteristics of BW373U86 in mice include antinociceptive
activity for the acetic acid-induced writhing and hot-plate
assays, along with increased locomotor activity and convul-
sions (Comer et al., 1993a; Wild et al., 1993). We now reportReceived for publication August 5, 1996
ABBREVIATIONS: NTI, naltrindole; b-FNA, b-funaltrexamine; MPE, maximal percent effect; DPDPE, lsqb]d-Pen2,D-Pen5]enkephalin; s.c., sub-
cutaneous.
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that data obtained with BW373U86 indicate that mu and
delta receptors interact, resulting in a modulation of opioid
side effects as well as antinociception in mice.
Methods
Animals. Male CD-1 mice (Charles River Laboratories, Raleigh,
NC) weighing 24 to 34 g on injection were housed in groups of 15 in
a temperature-controlled room (2261°C) on a 12-hr dark/light cycle
with food and water available ad libitum.
Analgesic testing. At the time of testing, 10 animals were placed
in a clean cage and transported to the laboratory. The mice were
given 1 hr to adapt to the new environment. Analgesic responses
were determined using a hot plate with timer (Ugo Basile, Varese,
Italy) and a temperature of 5560.5°C as the nociceptive stimulus.
Each mouse was removed from the hot plate when either a jumping
escape response occurred, hind paws were licked or a maximal cutoff
time of 50 sec was reached. Two initial preinjection analgesia read-
ings were collected as control measures. The first was used as a
habituation procedure and was disregarded. The second, taken 5 to
10 min later, was used as the pre-injection control base-line response
time. Drugs were administered by an s.c. route of injection at the
back of neck. Hot-plate measures were performed at 10-, 30- and
60-min time intervals after drug treatment. Thereafter, measure-
ments were taken in 30-min intervals until drug action had termi-
nated.
Convulsion scoring. Groups of 10 mice were injected s.c. with
test drugs, and the percentage of animals that showed a seizure
response was scored. To achieve a positive seizure score, subjects
must have exhibited convulsive activity followed by a period of cat-
alepsy. Convulsive activity was characterized by clonic movements
that encompassed the entire body. The postictal period of catalepsy
was characterized by a loss of locomotor activity for a 5- to 15-min
period and a loss of the righting reflex. Normal behavior patterns
were typically resumed after the cataleptic period.
Straub tail measures. Straub tail effect values were recorded by
visual observation with the use of a protractor. Straub tail scores
were recorded using the horizontal as 0 degrees and measuring the
increase of tail curvature in 15-degree increments up to 90 degrees.
Drugs. Drugs used in the study were BW373U86 (Burroughs
Wellcome, Research Triangle Park, NC), fentanyl citrate (Sigma
Chemical, St. Louis, MO), midazolam (Hoffmann-LaRoche, Nutley,
NJ), b-FNA hydrochloride (Research Biochemicals, Natick, MA) and
NTI (synthesized according to Portoghese et al., 1988a). BW373U86
and the delta antagonist NTI (Portoghese et al., 1988b) were dis-
solved in a 0.9% NaCl solution to concentrations used in the text.
b-FNA and fentanyl were dissolved using water to the required
concentrations. Some dimethylsulfoxide (15% of the total volume)
was used to enhance the solubility of midazolam. Fentanyl and
BW373U86 were often coadministered. They were each dissolved in
a stock solution, and then the required volume of each was pipetted
to a separate vial to reach final concentrations. To ensure that
receptors were saturated, the opioid antagonists and midazolam
were administered at a set time before the individual agonist or
mixed agonists were injected. Midazolam was injected 10 min and
NTI was injected 20 min before mu and delta agonist administration.
b-FNA was injected once every 24 hr over a 3-day period (total of
three injections). Mu and delta agonists were administered 24 hr
after the last b-FNA injection.
Data analysis. Statistical analyses were performed on all data
using an analysis of variance, the Student’s t test or a x2 test,
depending on the nature of the data. Differences were considered to
be significant at a P , .05 level. ED50 values were calculated with
regression equations plotted on a probit scale. The following equa-
tion was used to determine the MPE score:
MPE 5
Postdrug latency 2 Predrug latency
50 2 Predrug latency 3 100% (1)
Results
Hot-plate antinociceptive response. Although the
delta opioid agonist BW373U86 was inactive in the hot-plate
assay with rats (Chang et al., 1993), in mice the compound
induced a time- and dose-dependent antinociceptive response
in the hot-plate assay (figs. 1 and 2). As in the rat,
BW373U86 appeared (by visual observation) to substantially
increase locomotor activity. In mice, hyperactivity persisted
for ;30 min, or during the period before the occurrence of a
convulsion. The antinociceptive response of BW373U86 (F 5
23.65, df 5 4/2, P , .0001) peaked at 10 min after the
injection, and the duration of action was short, lasting ;45 to
60 min at the highest dose tested (fig. 1). The antinociceptive
effects of BW373U86 were produced with a 0.5 mg/kg dose
and reached a nearly maximal effect at an s.c. dose of 10
mg/kg (fig. 2). The ED50 values for the production of analgesic
and seizure effects by BW373U86 were 2 and 5 mg/kg, re-
spectively.
The mu agonist fentanyl was also observed to produce
analgesia (ED50 5 50 mg/kg), and the coadministration of
BW373U86 and fentanyl produced additive antinociceptive
effects (fig. 3). Results do not demonstrate a clear potentia-
tion of analgesic activity (note the similarity of slopes be-
tween doses in fig. 3). Most importantly, analgesic effects of
fentanyl were not decreased after BW373U86 administra-
tion, and thus the delta and mu agonists do not have antag-
onistic effects in a hot-plate paradigm. The BW373U86-in-
duced hot-plate antinociceptive response was antagonized by
the delta antagonist NTI (F 5 27.8, df 5 3/7, P , .0003),
which did not affect fentanyl analgesia (F 5 0.55, df 5 2/6,
P 5 NS; fig. 4A). Analgesia induced by 10 mg/kg BW373U86
s.c. was effectively blocked by a 0.5 mg/kg dose of NTI,
suggesting that the hot-plate antinociceptive activity of
BW373U86 was mediated by delta receptors. Antagonism of
delta receptors does not, however, play a significant role in
modulating the analgesic effects produced by fentanyl (fig.
4A). The anticonvulsant midazolam did not have analgesic
Fig. 1. Time course of the antinociceptive effect of BW373U86 (0.5–10
mg/kg s.c.) in the mouse hot-plate assay. Hot-plate analgesic effects
were produced by BW373U86, in a dose-dependent manner. Antino-
ciceptive effects peaked at ;10 min after injection and declined to
base-line levels within 1 hr. Data are plotted with smooth spline curves
and are presented as mean 6 S.E., with 10 to 40 mice in each dose
group.
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effects and did not affect the analgesia produced by
BW373U86 (fig. 4B).
Fentanyl attenuates the convulsive response of
BW373U86. Convulsions produced by BW373U86 in mice
are brief, nonreoccurring incidents that are typically followed
by a period of catalepsy (Comer et al., 1993a). In the present
study, the minimal dose needed to produce convulsions in at
least 1 mouse in a group of 10 was 1 mg/kg s.c. Convulsive
activity occurred in 80% of the animals with a dose of 10
mg/kg s.c. (fig. 5). The convulsive activity of BW373U86 is
about 2.5-fold less potent than the antinociceptive activity
(fig. 2). The administration of the delta antagonist NTI an-
tagonized the convulsive effects of BW373U86 in a dose-
dependent manner (fig. 5; x2 5 30.9, df 5 3, P , .0001). A
dose of 1 mg/kg of NTI completely eliminated convulsions
induced by 10 mg/kg BW373U86. As observed by Comer et al.
(1993a), BW373U86-induced convulsive activity was com-
pletely blocked by the anticonvulsant midazolam at a dose of
3.2 mg/kg s.c. (fig. 5; x2 5 36.7, df 5 1, P , .0001).
The data from figure 2 do not reveal whether 373U86-
induced increases in hot-plate latencies represent true an-
tinociception or are, in part, a reflection of animals being
behaviorally compromised by some degree of convulsive ac-
tivity. Most importantly, the data from figures 4B and 5
indicate that the antinociceptive effect of BW373U86 is not a
consequence of convulsive effects. When BW373U86 seizure
activity is blocked by midazolam (fig. 5), the hot-plate antino-
ciceptive response of BW373U86 still occurs (see fig. 4B).
Fentanyl did not have convulsive activity at doses tested
up to 500 mg/kg s.c. Administration of the mu agonist fenta-
nyl did, in a dose-dependent manner, reduce the percentage
of mice that had BW373U86-induced seizures (McNemar’s x2
5 193.3, df 5 6, P , .0001) but did not completely eliminate
all convulsions (fig. 6). These results lead to the conclusion
that mu receptors can modulate BW373U86-induced convul-
sive activity. To confirm this, a study was performed using
b-FNA, a specific and irreversible mu opioid antagonist
(Jiang et al., 1990a, 1990b; Takemori and Portoghese, 1985;
Ward et al., 1982) to test the hypothesis that mu receptors
can modulate BW373U86-induced convulsive activity.
Mice were injected (s.c.) a total of three times with 10
mg/kg b-FNA (once a day over a 3-day period). The antino-
ciceptive effect of fentanyl was significantly reduced from
maximum levels to ;50% of the MPE after b-FNA pretreat-
ment (t 5 4.36, df 5 2, P , .05; fig 7A). The antinociceptive
effect of BW373U86 was not affected by b-FNA pretreatment
(t 5 0.67, df 5 5, NS). These data confirm that b-FNA
treatment under the present protocol produced selective an-
tagonistic effects at mu-, but not delta-, opioid receptors.
BW373U86-induced seizure activity was again observed to
be significantly attenuated by fentanyl administration (fig. 7;
x2 5 21.5, df 5 1, P , .0001). Interestingly, the convulsive
effect of BW373U86 appeared to be slightly decreased from
80% to 67% after b-FNA treatment, but the effect was not
observed to be significant (x2 5 0.63, df 5 1, P 5 NS; fig. 7B).
It is unknown whether the current b-FNA treatment, by
Fig. 3. The effects of BW373U86 on fentanyl-
induced analgesia. Both fentanyl (0, 50, 100,
200 and 400 mg/kg) and BW373U86 were ad-
ministered s.c. immediately before testing. An-
algesic effects were then measured in a hot-
plate apparatus at 10-, 30- and 60-min time
points after the injections. Note that slopes are
similar across all doses at each time point.
BW373U86 and fentanyl each produced anal-
gesic effects that were additive when com-
bined. Data are presented as mean 6 S.E. with
10 to 40 mice in each dose group.
Fig. 2. Dose-response curves for BW373U86 (0.5–10 mg/kg s.c.) in
the hot-plate assay and for BW373U86-induced convulsions. Plots are
obtained from data collected at the peak effective time point of
BW373U86 (e.g., 10 min). BW373U86 produced analgesic effects and
seizure activity in a dose-dependent manner. Data are presented as
mean 6 S.E. with 10 to 40 mice in each dose group. A second-order
regression line is fitted and plotted with the data.
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itself, would have altered nociceptive or seizure thresholds;
however, published reports of studies that used similar meth-
ods do not reveal any such effects of b-FNA (Heyman et al.,
1989a; Jiang et al., 1991). b-FNA treatment did, however,
antagonize the ability of fentanyl to attenuate BW373U86-
induced seizure activity (x2 5 7.3, df 5 1, P , .007,
BW373U86 1 fentanyl group vs. BW373U86 1 fentanyl 1
bFNA group). In b-FNA-pretreated mice that received a 10
mg/kg dose of BW373U86 and a 200 mg/kg fentanyl dose,
convulsive activity returned from 20% to nearly 60% com-
pared to the same dose treatment without preinjected b-FNA
(fig. 7B). There was no significant difference between the
data for the group that received all three treatments and the
group that received BW373U86 and b-FNA, suggesting that
fentanyl did not attenuate BW373U86 seizure activity in
b-FNA-treated mice (x2 5 0.39, df 5 1, P 5 NS). Overall,
results indicate that the ability of fentanyl to block
BW373U86-induced seizures is due to mu receptor activity.
BW373U86 inhibits fentanyl-induced Straub tail ef-
fect. Muscle rigidity is one of the side effects of fentanyl that,
in mice, results in a Straub tail effect. The degree of tail
curvature increases proportionally as the dose of fentanyl is
increased (fig. 8). The administration of BW373U86 de-
creased fentanyl-induced Straub tail in a dose-dependent
manner (F 5 69.4, df 5 5/458, P , .0001; fig. 8). NTI was
administered to mice in combination with BW373U86 and
fentanyl to test the hypothesis that the BW373U86 inhibi-
tory effect on fentanyl-induced muscle rigidity is the result of
delta receptor activation. Neither BW373U86 nor NTI alone
induced the Straub tail effect in mice (fig. 9). Results depicted
in figure 9 illustrate that fentanyl produced ;30 degrees of
Straub tail curvature at a 150 mg/kg dose s.c. BW373U86, at
a 10 mg/kg dose, almost completely inhibited the Straub tail
effect induced by 150 mg/kg fentanyl (t 5 8.3, df 5 58, P ,
.0001). NTI (0.5 mg/kg s.c.) also reduced Straub tail curva-
Fig. 4. A, Dose-response curves of NTI (0.1–1
mg/kg s.c.) on BW373U86 (10 mg/kg s.c.) and
fentanyl (150 mg/kg s.c.) analgesic effects in a
hot-plate assay. Data are presented as mean 6
S.E. with 20 to 30 mice in each experiment. The
administration of NTI dose-dependently antag-
onized BW373U86- but not fentanyl-induced
analgesic effects. B, Hot-plate analgesic ef-
fects of BW373U86 (10 mg/kg s.c.) in mice
pretreated with midazolam (3.2 mg/kg s.c.) and
for midazolam alone. Analgesic effects of
BW373U86 were still observed after midazolam
administration at a dose that does block seizure
activity (see fig. 5). Data are presented as
mean 6 S.E. with 30 mice in each dose group.
Fig. 5. Effect of the delta antagonist NTI and midazolam on
BW373U86-induced convulsions. NTI (0.2–1 mg/kg s.c.) dose-depen-
dently antagonized the ability of BW373U86 (10 mg/kg s.c.) to produce
seizures. The anticonvulsant midazolam (3.2 mg/kg s.c.) also blocked
BW373U86-induced seizure activity at a dose that does not affect
analgesia (see fig. 4). p, Significant difference from BW373U86-treated
control animals that did not receive NTI. Convulsive scores of
BW373U86 in mice pretreated with NTI or midazolam are presented as
mean 6 S.E. with 30 mice in each dose group.
Fig. 6. Effect of fentanyl on the convulsions induced by BW373U86.
BW373U86 (1–10 mg/kg s.c.) dose-dependently increased the percent-
age of animals that experienced seizures, and fentanyl (50–400 mg/kg
s.c.) blocked BW373U86-induced seizure activity in a dose-dependent
manner. The convulsive score of BW373U86 in control mice and in
mice with coadministered fentanyl are presented as mean 6 S.E. with
30 to 50 mice in each dose group.
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ture from 30 degrees to ;18 degrees (t 5 3.23, df 5 58, P ,
.002) but did not eliminate the occurrence of Straub tail (fig.
9). A possible explanation for this effect is that NTI does have
some affinity for mu receptors and thus can exhibit mu
antagonist effects (Portoghese et al., 1988b). When fentanyl,
BW373U86 and NTI were coadministered, the degree of cur-
vature was ;15 degrees, which was significantly different
from the 5-degree curvature observed in subjects treated
with fentanyl and BW373U86 (t 5 4.65, df 5 58, P , .0001).
Results indicate that NTI administration can, at least par-
tially, antagonize the ability of BW373U86 to block fentanyl-
induced Straub tail. The degree of tail curvature was re-
turned to the level produced by NTI alone (fig. 9). Results
indicate that the delta agonist BW373U86 can inhibit
fentanyl-induced Straub tail through direct effects on delta
receptors.
Discussion
Previous reports (Comer et al., 1993a; Wild et al., 1993)
described antinociceptive effects of BW373U86 in acetic acid-
induced writhing and tail-flick tests in mice. The present
studies confirm the antinociceptive activity of BW373U86 in
a 55°C hot-plate test in mice. Analgesic effects of BW373U86
do not appear to be a consequence of seizure activity, because
antinociceptive effects are still observed when seizure activ-
ity is blocked with the anticonvulsant midizolam (figs. 4 and
5). The hot-plate antinociceptive activity of BW373U86 was
antagonized by NTI at doses of ,1 mg/kg. In contrast, the
irreversible mu antagonist b-FNA, under conditions that sig-
nificantly reduce the antinociceptive response of the mu ag-
onist fentanyl, did not affect the antinociceptive effect of
BW373U86. Convulsive activity induced by BW373U86 was
also antagonized by NTI in a dose-dependent manner (fig. 5).
The data provide evidence that BW373U86 produces antino-
ciceptive and convulsive effects in mice through actions at
NTI-selective delta receptors.
Fig. 7. Antagonistic effect of b-FNA on the ability of fentanyl to atten-
uate BW373U86-induced seizure activity. A, Treatment with the irre-
versible mu antagonist b-FNA significantly antagonized the analgesic
effects of fentanyl. p, Significant difference compared with the fentanyl
dose group. B, Fentanyl (200 mg/kg s.c.) can attenuate the percentage
of animals that experience seizures after receiving BW373U86 (10
mg/kg s.c.). The attenuating effect of fentanyl is apparently due to mu
receptor activation because the irreversible mu antagonist b-FNA (10
mg/kg s.c. injections 3 3) can block the ability of fentanyl to attenuate
BW373U86-induced seizure activity. p, Significant differences from
groups with identically numbered asterisks. Convulsive and analgesic
scores are presented as mean 6 S.E. with 20 to 50 mice in each dose
group.
Fig. 8. Antagonistic modulation of BW373U86 on the fentanyl-induced
Straub tail response in mice. The degree of tail curvature increased
proportionally as the dose of fentanyl was increased from 50 to 400
mg/kg s.c. BW373U86 (0.5–10 mg/kg s.c.) dose-dependently antago-
nized muscle rigidity effects of fentanyl that resulted in a Straub tail
response. The dose-response curve for the effect of coadministration
of BW373U86 on fentanyl-induced Straub tail are presented as mean 6
S.E. with 8 to 40 mice in each dose group.
Fig. 9. Effect of NTI on the BW373U86 modulation of fentanyl-induced
Straub tail. The ability of BW373U86 (10 mg/kg s.c.) to antagonize
Straub tail induced by fentanyl (150 mg/kg s.c.) was partially blocked by
the delta antagonist NTI (0.5 mg/kg s.c.). p, Significant differences from
groups with identically numbered asterisks. Data are presented as
mean 6 S.E. with 10 to 30 mice in each dose group.
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A potentiation and modulation of the antinociceptive re-
sponse of morphine by delta agonist peptides has been pre-
viously documented (Heyman et al., 1989a, 1989b; Vaught
and Takemori, 1979). Dykstra et al. (1993) also demonstrated
that BW373U86 potentiates morphine and L-methadone an-
tinociception in an electric shock titration assay in monkeys.
In the present study, we were unable to demonstrate a clear
potentiation by BW373U86 of the antinociceptive response of
fentanyl in the mouse hot-plate test. The antinociceptive
effect of fentanyl and BW373U86 in our hot plate test was
purely additive. This finding is not surprising because the
potentiating effect of delta agonists has not been reported for
highly efficacious mu agonists (i.e., , [D-Ala2,N-MePhe4,Gly-
ol5]enkephalin, PL 017 and sufentanil; Heyman et al.,
1989b). Fentanyl is known to be a highly effective mu agonist
(Jiang et al., 1990b; Porreca et al., 1992; Stevens and Yaksh,
1989), and thus BW373U86 would not be expected to poten-
tiate analgesia induced by fentanyl.
The interactive modulation of mu and delta receptor effects
can be extended to effects of the nonpeptide delta agonist
BW373U86 and the selective mu agonist fentanyl. In mice,
BW373U86 induces seizure activity via delta receptor acti-
vation. The mu opioid agonist fentanyl can antagonize the
ability of BW373U86 to produce seizures. Additionally, the
selective mu antagonist b-FNA significantly blocked the abil-
ity of fentanyl to inhibit seizures produced by BW373U86
(fig. 7). Thus, the ability of BW373U86 to produce seizures
can be attenuated by fentanyl through an agonist action at
mu receptors.
Fentanyl also induces muscle rigidity, such as Straub tail,
through mu receptor activation. Conversely, fentanyl-in-
duced muscle rigidity can be inhibited by the delta agonist
BW373U86. Apparently, delta receptor effects of BW373U86
inhibit mu agonist-induced muscle rigidity, because the delta
antagonist NTI can partially antagonize the ability of
BW373U86 to inhibit fentanyl-induced Straub tail (fig. 9).
The present data indicate that a delta opioid agonist can
attenuate some effects of a mu agonist (i.e., muscle rigidity)
and a mu agonist can antagonize some effects of a delta
agonist (i.e., seizure activity). Interestingly, the delta agonist
BW373U86 and the mu agonist fentanyl can selectively an-
tagonize each other’s effects because a combination of the two
agonists results in additive analgesic effects.
It is curious that Straub tail was not observed after fent-
anyl and BW373U86 administration, when Straub tail has
been reported to be produced by the delta peptide DPDPE
(Murray and Cowan, 1990). We have never observed a Straub
tail response in male CD1 mice after the administration of
specific nonpeptide delta agonists. As suggested by Murray
and Cowan (1990), the Straub tail response seen after DP-
DPE administration is probably due to mu receptor activa-
tion. The question of why delta effects of DPDPE failed to
block the mu-induced Straub tail remains unanswered, but
critical factors could be the strain of mouse used or pharma-
codynamic differences produced by the route of administra-
tion (s.c. vs. intracerebroventricular).
A previous report described the existence of a mu and delta
interaction in a rat model of opioid dependence. Lee et al.
(1993) demonstrated that BW373U86 does not produce phys-
ical dependence alone but can attenuate the development
and expression of abstinence precipitated by naloxone in
morphine-dependent rats. Our data clearly indicate that a
complex in vivo interaction takes place between delta- and
mu-mediated effects in mice. It will be interesting to find out
whether similar interactions occur in other species and with
other opioid effects.
In conclusion, many complex interactions occur between
mu and delta receptors. These effects contribute to the mod-
ulation of antinociception and side effects. In our study,
BW373U86 decreased fentanyl-induced muscle rigidity (e.g.,
Straub tail), whereas fentanyl decreased the convulsions
caused by BW373U86. Coadministration of both compounds
produced an additive analgesic effect in a mouse hot-plate
assay. Further studies are clearly needed to provide a de-
tailed understanding of the intricate interaction that takes
place between delta- and mu opioid receptors.
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